Ocean Biomedical, Inc.

Ocean Biomedical, Inc. is a U.S.-based biopharmaceutical company focused on discovering and developing drug candidates in oncology, fibrosis, and infectious disease. Its business centers on advancing preclinical and clinical-stage programs, protecting intellectual property, and, if successful, moving candidates through regulatory approval toward commercialization or licensing.

0.02

— Ocean Biomedical, Inc.
	%
Preclinical programs	40% Discovery-stage therapeutic assets being advanced through research and early development.
Clinical-stage programs	35% Drug candidates in human trials across oncology, fibrosis, and infectious disease.
Manufacturing and process development	10% Work to produce drug material and prepare late-stage and commercial manufacturing processes.
Licensing and partnering	10% Potential out-licensing or collaboration structures tied to product candidates and IP.
Intellectual property portfolio	5% Patent and know-how assets supporting candidate development and partnering value.

Ocean Biomedical does not currently sell commercial products, so its near-term counterparties are research...

Research universities and medical centersprimary
Provide licensed discoveries, scientific collaboration, and translational research support.
Contract development and manufacturing organizationsprimary
Manufacture preclinical and clinical drug material and support process development.
Clinical research ecosystemprimary
Trial sites, CROs, and service providers that execute preclinical and clinical studies.
Potential licensing and commercialization partnerssecondary
Pharmaceutical partners that may license assets or help commercialize approved products.
Future healthcare providers and patientsemerging
End users of approved therapies in oncology, fibrosis, or infectious disease.

Ocean Biomedical is headquartered in the United States and operates as a U.S. public biotechnology company...

•Headquartered in the United States
•Primary operating footprint is U.S.-based research and corporate activity
•Clinical and manufacturing partners may be located outside the company
•No product revenue disclosed, so no country revenue mix is available

The company’s strategy is to advance a pipeline of oncology, fibrosis, and infectious disease candidates from...

Advance pipeline candidates into the clinicshort-term

Clinical entry is the key value-creation step for a pre-commercial biotech company.

Secure regulatory approvalsmedium-term

Approval is required before any candidate can be sold or broadly commercialized.

Build manufacturing and commercialization capabilitymedium-term

Late-stage development requires reliable supply and a path to market.

Protect and expand intellectual propertylong-term

Patent protection supports partnering leverage and future exclusivity.

Ocean Biomedical faces the typical risks of an early-stage biotechnology company: its candidates may fail in...

critical

Financing and liquidity risk

The company has no product revenue and depends on external capital to fund operations.

Scope: Working capital, R&D, and debt service
Materiality: high

high

Clinical and development failure

Therapeutic candidates must succeed through preclinical and clinical testing before approval.

Scope: Pipeline programs in oncology, fibrosis, and infectious disease
Materiality: high

high

Regulatory approval risk

Even promising candidates require successful regulatory review before commercialization.

Scope: All product candidates
Materiality: high

high

Debt and dilution risk

Outstanding convertible notes and warrants can pressure cash needs and share count.

Scope: Convertible debt and equity-linked financing
Materiality: high

medium

Intellectual property risk

Value depends on obtaining and protecting patents and licensed rights.

Scope: Licensed assets and proprietary technology
Materiality: medium

Convertible notes and warrants

Can materially affect liabilities, equity, and reported earnings

Backstop put option liability

May create volatility in other income/expense

Research and development expense recognition

Drives reported burn and comparability across periods

Accrued expenses and external service estimates

Can shift expenses between periods

Ocean Biomedical, Inc.

Financing and liquidity risk

Clinical and development failure

Regulatory approval risk

Debt and dilution risk

Intellectual property risk

ORAGENICS INC

GENELUX Corp

Oncotelic Therapeutics, Inc.

LeonaBio, Inc.

IMPACT BIOMEDICAL INC.

Propanc Biopharma, Inc.